politics
Trump Administration Considers Most Favored Nation Drug Pricing Policy
The proposal would link U.S. prescription drug prices to the lowest prices paid by foreign governments. A patient advocate argues the approach could reduce funding for pharmaceutical research and limit patient access to new medicines.
May 26, 9:00 AM·1m read1 source
Washington ExaminerAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
U.S. drug prices to the lowest prices paid by foreign governments. U.S. market. U.S. research spending in half, resulting in roughly 500 fewer new medicines over the next decade.
Japan applies mandatory annual price reductions regardless of a drug’s clinical value. Japanese patients gained access to 43 percent of newly launched medicines worldwide in recent years, compared with more than 80 percent for American patients. The United Kingdom, France, and Italy use health technology assessments that often assign lower value to treatments for older adults and people with chronic conditions.
A study of 19 other high-income countries found patients there have access to 36 percent of the newest medicines, while Americans have access to 88 percent.
Spiegel, executive director of the Global Colon Cancer Association, said a Section 301 investigation into foreign pricing practices would give the United States leverage to press other nations to contribute more to research costs. U.S. market.
